Tirzepatide in PWS, HO and GNSO
NCT06901245
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prader-Willi Syndrome
- Hypothalamic Obesity
- Obesity/Therapy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 26 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Grace Kim
- Last updated on ClinicalTrials.gov
- September 16, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Minnesota · 1
- Children's Minnesota · Saint Paul, MN
Tennessee · 1
- Vanderbilt University Medical Center · Nashville, TN
Washington · 1
- Seattle Children's Hospital · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.